Health Ministry's Drug Technical Advisory Body (DTAB) has recommended that the ban on anti-diabetes drug Pioglitazone and Analgin should be lifted, reports Archana Shukla of CNBC-TV18.
The health ministry's Drug Technical Advisory Body (DTAB) has recommended that the ban on anti-diabetes drug Pioglitazone and painkiller Analgin be lifted, reports CNBC TV18’s Archana Shukla, quoting sources.
DTAB, in its review on Friday, said that Pioglitazone should be allowed in the market with a list of warnings in the package insert of the drug. The Health Ministry is expected to finalise the revocation next week.
Health Ministry had banned Pioglitazone in June, owing to possible links to bladder cancer. The ban was opposed by the medical fraternity and the drug industry as being a hasty decision. They protested that the decision was not based on proper studies and consultation. The drug is banned in France, but is sold in the US and Europe with box warnings.
Pioglitazone has a market size of over Rs 700 crore in India and pharmaceutical companies like Lupin , Sun Pharma , and USV, would benefit from this revocation. Around 30 lakh patients are currently dependent on the drug will be beneficiaries of the revoking of this ban. If the ban gets continued, patients would have had to shift to more expensive treatments like Gliptins.
READ MORE ON drug, health ministry, drug technical advisory body, dtab, pioglitazone, analgin, package, pharmaceuticals, hasty decision, banning, opposition, us, europe, lupin, sun pharma, usv, revocation, anti diabetes
Set email alert for
ADS BY GOOGLE
video of the day
Rupee weakness modest, see yields at 7.60% in Q1: Deutsche